Ravi Dharamshi, CIO, ValueQuest Investment Advisors who tracks pharma very closely says that Covid crisis acted as a catalyst for pharma stocks to rally but Indian pharma companies have more legs for growth across the region and the rally is not only related to Covid. He added that growth opportunity for Indian Pharma companies in the US is large with high growth areas like Biosimilars, Inhalers & Complex Molecules. He also said that API players in India are looking interesting at global giants look to source API from Indian Markets.
Catch the Full Interview with Ravi Dharamshi CIO of ValueQuest Investment Advisors here: